• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aridis Pharmaceuticals Inc. - Common Stock (NQ:ARDS)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 18, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aridis Pharmaceuticals Inc. - Common Stock

News headline image
Reviva Pharmaceuticals Holdings, Inc. and Aridis Pharmaceuticals, Inc. Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
September 22, 2023
Via ACCESSWIRE
News headline image
Aridis Pharmaceuticals, Inc., Genetic Technologies Limited, and American Resources Corporation Interviews to Air on the RedChip Money Report® on Bloomberg TV
September 15, 2023
Via ACCESSWIRE
News headline image
Aridis Pharmaceuticals and Rail Vision Interviews to Air on Bloomberg TV on the RedChip Money Report(R)
June 30, 2023
Via ACCESSWIRE
News headline image
FDA Provides Positive Feedback for Aridis Pharmaceuticals’ (NASDAQ: ARDS) AR-301 Phase 3 Study
May 31, 2023
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) receives encouraging input from the FDA for the proposed confirmatory Phase 3 trial of AR-301, 
Via Spotlight Growth
News headline image
Interviews with Rail Vision, Aridis Pharmaceuticals, and Digital Ally to Air on Bloomberg U.S. on the RedChip Money Report(R)
February 17, 2023
Via ACCESSWIRE
News headline image
(Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
December 12, 2022
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation
December 12, 2022
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Signs Exclusive Terms to Secure Worldwide Commercial Licenses for Pan-Ebola and Pan-Marburg Monoclonal Antibody Programs from Mapp Biopharmaceutical
December 05, 2022
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase 2a Study of AR-501 in Cystic Fibrosis Patients
November 30, 2022
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis to Participate in Key Opinion Leader Discussion on Immunotherapy for Infectious Diseases
November 22, 2022
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
November 21, 2022
From Aridis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
RedChip Interviews Aridis Pharmaceuticals' CEO Vu Truong
June 30, 2022
ORLANDO, FL / ACCESSWIRE / June 30, 2022 / RedChip Companies will air a new C-Level interview with Aridis Pharmaceuticals (NASDAQ:ARDS) on The RedChip Money Report® on Bloomberg TV, this Saturday, July... 
From RedChip
Via AccessWire
News headline image
Medical Breakthrough: CRISPR Gene Editing Technology from MIT and Harvard Phase 3: Aridis Pharmaceuticals (Nasdaq: ARDS)
June 10, 2021
NASDAQ Co. Focused on CRISPR Gene Editing Technology from the Broad Institute of MIT and Harvard: Aridis Pharmaceuticals, Inc. (Stock Symbol: ARDS) 
Via EIN Presswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap